Johnson & Johnson is the world's largest and most diverse healthcare firm... Show more
Johnson & Johnson is one of the world's largest and most diversified healthcare companies, operating through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and sells pharmaceuticals across oncology, immunology, neuroscience, cardiovascular, and pulmonary hypertension, anchored by blockbusters such as DARZALEX, TREMFYA, and CARVYKTI. The MedTech segment spans surgical technologies, orthopaedics, cardiovascular devices, and vision care. Investors follow the stock for its defensive cash flows, decades-long record of dividend growth, and its stated ambition to become a global leader in oncology while expanding into robotic surgery and other fast-growing device categories.
Over the trailing 30 days, JNJ shares rose approximately 10.6%, moving from a close near $255.56 to about $282.77 at the latest available price. The trend was not a straight line: shares consolidated in mid-October before breaking higher in late October and November, culminating in a record high near $282.03 in early November.
Looking at the broader trailing quarter, the stock has gained roughly 7.8% from its mid-August level near $262.37. That multi-month advance reflects an improving growth narrative in pharmaceuticals, even as the market weighed softer MedTech results and a sizable one-time legal charge reported with third-quarter earnings.
The recent advance has been supported by several verified catalysts. In mid-October, Johnson & Johnson reported third-quarter worldwide sales of $25.4 billion, up about 5.9% year over year, with adjusted diluted EPS of $2.59. Management also raised full-year 2026 guidance, lifting the midpoint of reported sales to roughly $101.2 billion and adjusted diluted EPS to about $11.10. Investors increasingly focused on the underlying operational strength, particularly in oncology and immunology, rather than the GAAP earnings hit from a proposed talc litigation resolution and acquisition-related costs.
In early November, the FDA granted accelerated approval to RYBREVANT FASPRO for adults with recurrent or metastatic head and neck squamous cell carcinoma, based on a confirmed overall response rate of 42% in the OrigAMI-4 trial. The approval expanded the oncology franchise and contributed to heavy trading volume and a push to record highs. A declared quarterly dividend of $1.34 per share and broad rotation into cash-generative healthcare names further supported sentiment, even as analysts noted the stock had begun to trade at a premium valuation.
The quarterly trend has been shaped by a larger narrative of portfolio transformation. Innovative Medicine delivered operational sales growth of 7.9% in the third quarter, led by double-digit gains across oncology assets including DARZALEX, CARVYKTI, and TECVAYLI, and by immunology and neuroscience products such as TREMFYA and CAPLYTA. Newer launches, including the oral psoriasis therapy ICOTYDE and the bladder-cancer treatment INLEXZO, strengthened the pipeline story.
These strengths helped investors look past a MedTech segment that grew only 2.5% operationally and fell short of internal expectations, with weakness concentrated internationally and in the Abiomed heart-recovery business. The quarter also featured regulatory milestones, including FDA De Novo authorization for the OTTAVA robotic surgery system, reinforcing a long-term growth narrative that has supported the stock's climb through record territory.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in this section. The featured bots vary widely in trading style, holding timeframe, and performance metrics, allowing users to review approaches that range from short-term signals to longer-horizon strategies. For investors tracking momentum in healthcare names, browsing these automated strategies can provide a complementary, data-driven perspective on market behavior.
Investors will be watching whether Innovative Medicine can sustain its above-market growth as newer products offset the ongoing loss of exclusivity on STELARA. The MedTech segment's trajectory, particularly any recovery in Abiomed and international surgery, will be a key swing factor, as will execution on the OTTAVA robotic platform launch. Further clarity on the proposed talc litigation resolution, the planned separation of the orthopaedics business, and any updates to 2027 guidance at the December Enterprise Business Review are additional items on the horizon. Macroeconomic and policy factors, including drug-pricing reform in the United States, also remain relevant to the broader pharmaceutical complex.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JNJ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 23 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 49%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 40 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
JNJ moved above its 50-day moving average on November 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 165 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor